Gastric Cancer:胃癌的代谢产物可以预测腹膜复发

2020-04-14 MedSci原创 MedSci原创

代谢组学可用于分析癌症进展所需的营养状况,本项研究评估了胃癌(GC)组织的代谢组学概况,以阐明代谢与癌症复发之间的关联。

背景:代谢组学可用于分析癌症进展所需的营养状况,本项研究评估了胃癌(GC)组织的代谢组学概况,以阐明代谢与癌症复发之间的关联。

方法:研究人员从140例行胃切除术的GC患者中获得癌症和相邻的非癌组织标本。将冷冻的组织匀浆并通过毛细管电泳飞行时间质谱(CE-TOFMS)进行分析。根据是否存在复发进一步评估癌症患者的代谢产物。

结果:研究人员共定量分析了九十三种代谢物。与非癌组织相比,在癌组织中,乳酸水平显着较高,腺苷酸能电荷较低。复发患者的Asp,β-Ala,GDP和Gly水平显着低于无复发患者。根据ROC分析确定四种代谢物的临界值,将患者分为腹膜复发的高风险和低风险组。Logistic回归和Cox比例风险分析确定β-丙氨酸是腹膜复发的独立预测因子([HR] 5.21 [95%置信区间1.07-35.89],p=0.029)和整体生存的独立预后因素(HR 3.44 [95%CI 1.65-7.14],p<0.001)。

结论:癌组织的代谢组学谱与非癌组织的代谢组学谱不同。另外β-丙氨酸既是腹膜复发的重要预测指标,也是预后因素。

原始出处:

Sanae Kaji. Et al. Metabolomic profiling of gastric cancer tissues identified potential biomarkers for predicting peritoneal recurrence. Gastric Cancer .2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072961, encodeId=e60020e29615a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Nov 29 17:22:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712385, encodeId=9f051e12385f3, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jun 16 09:22:03 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893666, encodeId=ac271893666f8, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Dec 01 08:22:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513468, encodeId=0c241513468cf, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623842, encodeId=914b1623842c1, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-11-29 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072961, encodeId=e60020e29615a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Nov 29 17:22:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712385, encodeId=9f051e12385f3, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jun 16 09:22:03 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893666, encodeId=ac271893666f8, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Dec 01 08:22:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513468, encodeId=0c241513468cf, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623842, encodeId=914b1623842c1, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072961, encodeId=e60020e29615a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Nov 29 17:22:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712385, encodeId=9f051e12385f3, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jun 16 09:22:03 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893666, encodeId=ac271893666f8, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Dec 01 08:22:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513468, encodeId=0c241513468cf, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623842, encodeId=914b1623842c1, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-12-01 skhzy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072961, encodeId=e60020e29615a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Nov 29 17:22:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712385, encodeId=9f051e12385f3, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jun 16 09:22:03 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893666, encodeId=ac271893666f8, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Dec 01 08:22:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513468, encodeId=0c241513468cf, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623842, encodeId=914b1623842c1, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2072961, encodeId=e60020e29615a, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sun Nov 29 17:22:03 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712385, encodeId=9f051e12385f3, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jun 16 09:22:03 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893666, encodeId=ac271893666f8, content=<a href='/topic/show?id=4fc4e85161' target=_blank style='color:#2F92EE;'>#gastric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7851, encryptionId=4fc4e85161, topicName=gastric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Dec 01 08:22:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513468, encodeId=0c241513468cf, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623842, encodeId=914b1623842c1, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Thu Apr 16 13:22:03 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-04-16 xuyong530

相关资讯

JGH OPEN:阿司匹林对胃癌的发生和生存的影响

最近发表的许多研究都在评估阿司匹林对胃癌的化学预防作用,因此,本研究旨在评估阿司匹林对胃癌发生和死亡的影响进行了荟萃分析。

中年女性,胃癌术后多年下肢肿胀2月余,请诊断!

中年女性,胃癌术后多年下肢肿胀2月余,请诊断!

Cell Death Dis:CD73通过调节RICS/RhoA信号及EMT进程促进胃癌转移

胃癌(GC)是全球范围的主要健康问题。转移性胃癌是一种致死性疾病,其生存率极低。肿瘤微环境(TME)在塑造癌症多样性过程中起着至关重要的作用,而CD73(ecto-5'-核苷酸酶; NT5E)在TME

纳武利尤单抗在中国获批胃癌三线治疗适应症

3月13日,百时美施贵宝宣布,纳武利尤单抗注射液(商品名为欧狄沃)已正式获得国家药监局批准用于治疗既往接受过两种或两种以上全身性治疗方案的晚期或复发性胃或胃食管连接部腺癌患者,成为第一个在中国获批用于

Cell Death Dis:PCDHGA9通过降低β-catenin转录活性抑制胃癌上皮-间质转化及转移潜能

PCDHGA9通过介导Wnt/β-catenin信号通路和TGF-β通路抑制上皮-间质转化(EMT)过程, 还能够抑制癌细胞的侵袭及转移.

病例:胃淋巴瘤与胃癌的影像学特点

病例 | 胃淋巴瘤与胃癌的影像学特点